Viking Therapeutics: Barbaric Value [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
Summary Viking therapeutics (NASDAQ: VKTX ) is a recent offshoot of Ligand Pharmaceuticals (NASDAQ: LGND ). It has six drugs in its pipeline, three farther along than the others. At a current valuation of roughly $22 million, with ~$0.75 in cash, the market is valuing its pipeline at a mere $10 million. Viking's top two candidates are: VK5211 currently in a phase two trial for osteoporotic hip fractures (seen in geriatric patients), and VK2809, in a phase two trial for dyslipidemias and non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition leading to non-alcoholic steatohepatitis (NYSEARCA: NASH ). Its third candidate, VK0214, is in development for treatment of X-linked Adrenoleukodystrophy, a rare, often fatal genetic disease. VK0214 was recently given orphan drug status by the FDA. Additionally, it has VK0612 in development for diabetes mellitus, type 2, and an erythropoietin-receptor agonist for anemia. Both VK5211 and VK2809 would address diseases that affect t
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights [Yahoo! Finance]Yahoo! Finance
- Viking (VKTX) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead [Seeking Alpha]Seeking Alpha
- Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024PR Newswire
- Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 2/7/24 - In-Line
VKTX
Sec Filings
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- VKTX's page on the SEC website